Conversation with The Cancer LetterCOVID-19 & CancerFree Ramon Parsons: How Mount Sinai did good science amid the COVID-19 deluge May 29, 2020Vol.46 No.22By Paul Goldberg
Drugs & TargetsFree Opdivo + Yervoy combination receives FDA approval for first-line mNSCLC (PD-L1 tumor expression ≥1%) May 22, 2020Vol.46 No.21
Drugs & TargetsFree Pomalidomide receives accelerated approval to for Kaposi sarcoma May 22, 2020Vol.46 No.21
Drugs & TargetsFree Rucaparib receives FDA approval for BRCA-mutated metastatic castration-resistant prostate cancer May 22, 2020Vol.46 No.21
Drugs & TargetsFree Ripretinib receives FDA approval for advanced gastrointestinal stromal tumor May 22, 2020Vol.46 No.21
Drugs & TargetsFree Tecentriq receives FDA approval as first-line monotherapy in NSCLC indication May 22, 2020Vol.46 No.21
Drugs & TargetsFree Olaparib receives FDA approval for HRR gene-mutated metastatic castration-resistant prostate cancer May 22, 2020Vol.46 No.21
Drugs & TargetsFree BRACAnalysis CDx receives approval as companion diagnostic for Lynparza in mCRPC indication May 22, 2020Vol.46 No.21
Drugs & TargetsFree Karyopharm submits sNDA for Xpovio as treatment for multiple myeloma after at least one prior line of therapy May 22, 2020Vol.46 No.21
Clinical RoundupFree Flatiron Health, Foundation Medicine, Genentech to launch novel prospective lung cancer clinical study May 22, 2020Vol.46 No.21
